SCHEMBL5770150

SCHEMBL5770150

COc1nc2ccc(Cl)cc2[nH]c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.55
ALDH1A1 P00352 2/20 0.54
AMY1A P0DUB6 10/20 0.52
HPGD P15428 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HTR3E A5X5Y0 1/20 0.50
HTR3B O95264 1/20 0.50
HTR3A P46098 1/20 0.50
BACE1 P56817 1/20 0.50
HTR3D Q70Z44 1/20 0.50
HTR3C Q8WXA8 1/20 0.50
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47
GRIN1 Q05586 1/20 0.47
GRIN2A Q12879 1/20 0.47
GRIN2B Q13224 1/20 0.47
GRIN2C Q14957 1/20 0.47
GRIN3A Q8TCU5 1/20 0.47
PSMB8 P28062 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5769991 0.88 HRH4 (0.52) EGFRALDH1A1GRIN2DGRIN3BGRIN1
SCHEMBL5774932 0.81 GRIN2D (0.54) ALDH1A1HPGDSMN1; SMN2GRIN2DGRIN3B
SCHEMBL6311370 0.79 ALDH1A1 (0.64) EGFRALDH1A1HPGDSMN1; SMN2HTR3E
SCHEMBL31495003 0.78 ALDH1A1 (0.58) EGFRALDH1A1HPGDSMN1; SMN2HTR3E
SCHEMBL5775034 0.78 NPBWR1 (0.50) MAPTHSD17B10
SCHEMBL5770141 0.77 GRIN2D (0.53) ALDH1A1AMY1AHPGDSMN1; SMN2GRIN2D
SCHEMBL5771862 0.77 GRIN2D (0.53) AMY1ASMN1; SMN2GRIN2DGRIN3BGRIN1
SCHEMBL5774049 0.77 PLAUR (0.56) ALDH1A1HPGDSMN1; SMN2HTR3AKDM4E
SCHEMBL31495062 0.77 HTR3E (0.66) EGFRALDH1A1HPGDSMN1; SMN2HTR3E
SCHEMBL5772209 0.74 ALDH1A1 (0.41) ALDH1A1AMY1AHPGDGRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670774-A1 QUINOXALINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-21 EP disclosed
WO-2005033088-A1 QUINOXALINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2005-04-14 WO disclosed
US-20050070527-A1 For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070527-A1 For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions HRH4, HRH3, LTB4R EGFR 3349/4885ALDH1A1 3818/4885AMY1A 4844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.